| Title |
Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer
|
|---|---|
| Published in |
Investigational New Drugs, October 2018
|
| DOI | 10.1007/s10637-018-0676-8 |
| Pubmed ID | |
| Authors |
Amit Mahipal, Sri Harsha Tella, Anuhya Kommalapati, Gaurav Goyal, Heloisa Soares, Anthony Neuger, Domenico Copolla, Jongphil Kim, Richard Kim |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Unknown | 43 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 14% |
| Researcher | 5 | 11% |
| Other | 4 | 9% |
| Student > Ph. D. Student | 3 | 7% |
| Student > Doctoral Student | 2 | 5% |
| Other | 7 | 16% |
| Unknown | 17 | 39% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 30% |
| Biochemistry, Genetics and Molecular Biology | 3 | 7% |
| Nursing and Health Professions | 1 | 2% |
| Unspecified | 1 | 2% |
| Immunology and Microbiology | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 22 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 October 2018.
All research outputs
#17,992,232
of 23,106,390 outputs
Outputs from Investigational New Drugs
#838
of 1,175 outputs
Outputs of similar age
#247,190
of 346,173 outputs
Outputs of similar age from Investigational New Drugs
#15
of 19 outputs
Altmetric has tracked 23,106,390 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,175 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 346,173 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.